NORD and C-Path Release Video on Rare Disease Challenges in Each Step of the Drug Development Process

Categorized in -

There are over 7,000 rare diseases, approximately 90% do not have FDA-approved treatments, and the process of developing therapies for rare diseases involves special challenges and considerations. NORD and the Critical Path Institute (C-Path) are working together on a new initiative, the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), bringing together data from different sources and providing tools for streamlining the steps of research and development to help researchers and drug developers overcome these difficulties. Watch video #2 in NORD and C-Path’s three-part video series, “Accelerating Rare Disease Drug Development,” which examines the challenges of developing therapies for rare diseases in each step of the drug development process. You can watch the video or learn more about the RDCA-DAP here: